What the FDA labels say about taking them together
Lithium and olmesartan
Olmesartan's FDA label of September 23, 2025 names lithium in its drug interactions section; the lithium labels PlainMeds reads (4) do not name olmesartan. The olmesartan label: “Increases in serum lithium concentrations and lithium toxicity.”
Check it at the source: the lithium FDA label on DailyMed (effective December 23, 2025, Glenmark Pharmaceuticals Inc., USA); the olmesartan FDA label on DailyMed (effective September 23, 2025, Cosette Pharmaceuticals, Inc.).
What does the lithium label say about olmesartan?
Lithium's label (effective December 23, 2025) and its 3 other brand-application labels do not name olmesartan in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Lithium Carbonate), Glenmark Pharmaceuticals Inc., USA, effective December 23, 2025 (SPL set 63b3790f-a9b5-47f4-bae1-ddf8b43c13c1), via openFDA; the full label on DailyMed
What does the olmesartan label say about lithium?
Olmesartan label, drug interactionsIncreases in serum lithium concentrations and lithium toxicity ( 7.4 ).
Source: FDA drug label (Benicar), Cosette Pharmaceuticals, Inc., effective September 23, 2025 (SPL set dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lithium | Olmesartan | |
|---|---|---|
| Labeled for | Bipolar disorder | High blood pressure |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.104 per capsule 300 mg capsule | $0.0805 per tablet 20 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once